Arrowstreet Capital, Limited Partnership Bei Gene, Ltd. Transaction History

Arrowstreet Capital, Limited Partnership

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$260.64 - $382.12 $8.02 Million - $11.8 Million	-30,782 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$221.31 - $316.61 $6.81 Million - $9.75 Million	30,782 New	30,782 $7.95 Million
Q4 2018 Feb 14, 2019	SELL	$107.01 - $175.15 $5.29 Million - $8.65 Million	-49,393 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$152.62 - $189.66 $489,452 - $608,239	-3,207 Reduced 6.1%	49,393 $8.51 Million
Q2 2018 Aug 14, 2018	BUY	$152.5 - $216.77 $8.02 Million - $11.4 Million	52,600 New	52,600 $8.09 Million

253

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $22.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.